23:21 , May 21, 2019 |  BC Extra  |  Company News

May 21 Company Quick Takes: Verily in deal with pharmas; plus Amryt-Aegerion, Prokaryotics

Verily, pharmas partner to develop clinical programs  The Verily Life Sciences LLC of Alphabet Inc. (NASDAQ:GOOG) partnered with Novartis AG (NYSE:NVS; SIX:NOVN), Otsuka Holdings Co. Ltd. (Tokyo:4578), Pfizer Inc. (NYSE:PFE) and Sanofi (Euronext:SAN; NASDAQ:SNY) to...
22:53 , Apr 5, 2019 |  BC Extra  |  Company News

Management tracks: Zealand taps Alnylam’s Dulac as CEO, plus ICER, Jnana and more

Emmanuel Dulac is leaving his post as chief international strategy officer of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) to become the new CEO of Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL), effective April 22. Dulac succeeds Adam Steensberg, the...
21:36 , Jan 26, 2019 |  BioCentury  |  Product Development

Raising the BD bar

Innovator biotechs say that the business development bar has been raised for companies developing new modalities, with potential partners seeking proof of mechanism on top of proof of efficacy. A host of products based on...
22:45 , Jun 20, 2018 |  BC Extra  |  Company News

Management tracks: Sanofi, NantKwest

Sanofi (Euronext:SAN; NYSE:SNY) hired Jean-Baptiste Chasseloup de Chatillon as EVP and CFO, effective Oct. 1. He was CFO and EVP at automotive company PSA Group (Euronext:UG). Natural killer cell company NantKwest Inc. (NASDAQ:NK) said Chief...
23:33 , Oct 6, 2017 |  BC Extra  |  Company News

Management tracks: Impel, InGeneron

Drug delivery company Impel NeuroPharma Inc. (Seattle, Wash.) named Jon Congleton president and CEO. He was president and CEO at Nivalis Therapeutics Inc. , which merged with Alpine Immune Sciences Inc. (NASDAQ:ALPN). Regenerative medicine company...
21:32 , Sep 29, 2017 |  BC Week In Review  |  Company News

Aegerion to pay fine for Juxtapid violations

Aegerion Pharmaceuticals Inc. will pay more than $40 million to the SEC and the U.S. Department of Justice to resolve allegations associated with Juxtapid lomitapide. The drug was approved in the U.S. in 2012 as...
23:18 , Sep 25, 2017 |  BC Extra  |  Company News

Aegerion to pay fine for Juxtapid violations

Aegerion Pharmaceuticals Inc. will pay more than $40 million to the SEC and the U.S. Department of Justice to resolve allegations associated with Juxtapid lomitapide. The drug was approved in the U.S. in 2012 as...
00:38 , Apr 1, 2017 |  BC Extra  |  Company News

Management tracks

Immuno-oncology company Forty Seven Inc. (Palo Alto, Calif.) named Mark McCamish CEO, effective May 1. He was global head of biopharmaceutical development at the Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN). Founding CEO Jonathan MacQuitty...
17:15 , Dec 9, 2016 |  BC Week In Review  |  Company News

Amryt, Aegerion deal

Aegerion granted Amryt exclusive rights to market Lojuxta lomitapide in the European Economic Area (EEA), Middle East and North Africa (MENA), Israel and Turkey. Aegerion is eligible for milestone payments, plus royalties. Amryt will be...
00:06 , Dec 3, 2016 |  BC Extra  |  Company News

Management tracks

Prescription and OTC pharma Taro Pharmaceutical Industries Ltd. (NYSE:TARO) said Uday Baldota will replace Kal Sundaram as its CEO, effective April 2017. Baldota is EVP and CFO at Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA). Abhay...